VERTEX PHARMACEUTICALS INC / MA
VERTEX PHARMACEUTICALS INC / MA is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 2, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.
VERTEX PHARMACEUTICALS INC / MA generates cash from operations, so a burn-based runway figure does not apply.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 2, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| January 30, 2028 | Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) | Trial Milestone | Phase 3 |
Track VRTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open VRTX in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| September 1, 2026 | 8-K filed: Leadership change | Corporate | — |
| August 12, 2026 | An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) | Trial Milestone | Phase 1/Phase 2 |
| August 3, 2026 | Quarterly results filed (8-K) | Earnings | — |
| July 7, 2026 | 8-K filed: Material agreement, Reg FD disclosure, Other event | Corporate | — |
| May 13, 2026 | 8-K filed: Leadership change | Corporate | — |
| May 4, 2026 | Quarterly results filed (8-K) | Earnings | — |
| April 29, 2026 | 8-K filed: Leadership change | Corporate | — |
| March 31, 2026 | 8-K filed: Other event | Filing | — |
| February 12, 2026 | Quarterly results filed (8-K) | Earnings | — |
| November 3, 2025 | Quarterly results filed (8-K) | Earnings | — |
| August 4, 2025 | Quarterly results filed (8-K) | Earnings | — |
| May 19, 2025 | 8-K filed: Other event | Filing | — |
| May 5, 2025 | Quarterly results filed (8-K) | Earnings | — |
| July 9, 2024 | ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus | Trial Milestone | Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.